Clinical Trial Update: Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients [Phase 2]

View source ↗

Summary

Phase IIa study evaluating the safety and efficacy of BL-8040 in relapsed/refractory acute myeloid leukemia has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BL-8040

Snippet

Sponsor: BioLineRx, Ltd. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19